Wu Xiaobin, president, chief operating officer and general manager of Baiji China, said at the media exchange meeting on the same day that the approval for commercialization of the Guangzhou biopharmaceutical production base will greatly increase the production capacity of Baze'an and other biopharmaceuticals in the research and development pipeline. PD-1 will not have overcapacity for quite some time, and the plant will also produce other protein drugs and monoclonal antibodies. At present, the clinical dosage of biopharmaceuticals in China is less than 10%, which is lower than the 30%-50% level in Europe and the United States.